A detailed history of Morgan Stanley transactions in Neuro Pace Inc stock. As of the latest transaction made, Morgan Stanley holds 2,483,983 shares of NPCE stock, worth $18.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,483,983
Previous 2,460,716 0.95%
Holding current value
$18.8 Million
Previous $25.4 Million 29.24%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$9.78 - $17.5 $227,551 - $407,172
23,267 Added 0.95%
2,483,983 $32.8 Million
Q4 2023

Feb 13, 2024

BUY
$5.9 - $10.31 $359,900 - $628,910
61,000 Added 2.54%
2,460,716 $25.4 Million
Q3 2023

Nov 15, 2023

BUY
$4.0 - $9.73 $163,400 - $397,470
40,850 Added 1.73%
2,399,716 $23.3 Million
Q2 2023

Aug 14, 2023

BUY
$3.98 - $5.12 $401,383 - $516,352
100,850 Added 4.47%
2,358,866 $10.6 Million
Q1 2023

May 15, 2023

BUY
$1.44 - $5.34 $99,969 - $370,718
69,423 Added 3.17%
2,258,016 $10.5 Million
Q4 2022

Feb 14, 2023

BUY
$1.29 - $2.98 $83,837 - $193,670
64,990 Added 3.06%
2,188,593 $3.26 Million
Q3 2022

Nov 14, 2022

BUY
$3.1 - $5.98 $429,083 - $827,715
138,414 Added 6.97%
2,123,603 $7.96 Million
Q2 2022

Oct 27, 2022

BUY
$4.95 - $8.7 $4.7 Million - $8.26 Million
949,405 Added 91.66%
1,985,189 $9.83 Million
Q2 2022

Aug 15, 2022

BUY
$4.95 - $8.7 $4.7 Million - $8.26 Million
949,405 Added 91.66%
1,985,189 $9.83 Million
Q1 2022

Oct 27, 2022

SELL
$7.06 - $11.57 $6.7 Million - $11 Million
-949,405 Reduced 47.82%
1,035,784 $8.5 Million
Q1 2022

May 13, 2022

BUY
$7.06 - $11.57 $5.43 Million - $8.9 Million
769,556 Added 289.06%
1,035,784 $8.5 Million
Q4 2021

Feb 14, 2022

BUY
$8.63 - $17.36 $2.23 Million - $4.49 Million
258,570 Added 3376.47%
266,228 $2.68 Million
Q3 2021

Nov 15, 2021

BUY
$15.85 - $25.07 $121,379 - $191,986
7,658 New
7,658 $121,000

Others Institutions Holding NPCE

About NeuroPace Inc


  • Ticker NPCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 24,846,900
  • Market Cap $188M
  • Description
  • NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...
More about NPCE
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.